<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01728922</url>
  </required_header>
  <id_info>
    <org_study_id>2012CIS/VD/SVUH</org_study_id>
    <nct_id>NCT01728922</nct_id>
  </id_info>
  <brief_title>Dose-related Effects of Vitamin D3 on Immune Responses in Patients With Clinically Isolated Syndrome</brief_title>
  <acronym>CISAVID</acronym>
  <official_title>Dose-related Effects of Vitamin D3 on Immune Responses in Patients With Clinically Isolated Syndrome and Healthy Control Participants. An Exploratory Double Blind Placebo Randomised Controlled Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College Dublin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Dublin, Trinity College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St Vincent's University Hospital, Ireland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University College Dublin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to assess the immune response to vitamin D
      supplementation at two doses (5,000 IU and 10,000 IU daily) in both healthy controls and
      patients with clinically isolated syndrome compared to placebo. Secondary endpoints include
      (1) disease outcome in the clinically isolated syndrome in terms of clinical relapses and
      evidence of new lesions on MRI (McDonald's MS), 2) Safety of doses used
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary endpoint: To determine the effects of vitamin D supplementation at two doses a) 5,000
      IU daily b) 10,000 IU daily compared to c) placebo a 24 weeks period on the change from
      baseline in frequency of CD4 T cell subsets and cytokine responses by peripheral blood
      mononuclear cells in 1) patients with the clinically isolated syndrome. 2) healthy control
      participants.

      Secondary endpoints:

        1. To determine whether there is a dose response effect of supplementation using 5,000 IU
           and 10,000 IU of vitamin D versus placebo over 24 weeks on the change from baseline in
           the frequency of CD4 T cell subsets and cytokine responses by PBMC in 1) patients with
           the clinically isolated syndrome (CIS) 2) healthy control participants

        2. To establish whether there is a clinical response to vitamin D measured by a) change in
           the number of T2 lesions and Gadolinium enhancing lesions on MRI scanning at 24 weeks
           compared to baseline b) reduction in relapses over 24 weeks in treated (both 5,000 IU
           and 10,000 IU) CIS patients versus CIS patients receiving placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 6, 2012</start_date>
  <completion_date type="Actual">June 5, 2016</completion_date>
  <primary_completion_date type="Actual">June 5, 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>double-blind, dose ranging, two doses of vitamin D, randomised parallel groups with placebo arms in clinically isolated syndrome and heathy control participants</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>similar appearance of placebo and active drug</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The effects of two doses of vitamin D and placebo therapy on the change in the frequency of CD4 T cell subsets and cytokine responses of PBMC over 24 weeks of therapy from baseline.</measure>
    <time_frame>This outcome measure will be assessed at baseline and at 24 weeks.</time_frame>
    <description>A number of measures will be examined in particular IL-10 production and the frequency of Th17 cells.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of new T2 and gadolinium enhancing lesions compared to baseline amongst the study group.</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>The MRI out-come measure will assess the a) number of Gadolinium enhancing lesions b) the number of new and enlarging T2 lesions c) the combined unique lesion count (new and enlarging T2 lesions plus Gadolinium enhancing lesions) after 24 weeks of therapy in the three arms, 5000IU, 10,000IU vitamin D and placebo . Mean and median new T2 and gadolinium-enhancing lesions at 24 weeks (end of the trial) will be compared for each treatment allocation group. In addition the mean and median number of new T2 lesions plus gadolinium enhancing lesions in all the CIS patients on vitamin D will be compared to the mean and median in the placebo group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse occurrence in the CIS patients during 24 weeks of the trial</measure>
    <time_frame>At each clinic visit or as the need arises.</time_frame>
    <description>Relapse occurrence in the CIS patients during 24 weeks of the trial;(i) annualised relapse rates (ARR), (ii) percentage of patients free from relapses and (iii) time to first relapse will be compared for each treatment allocation group. In addition the same relapse measures will be applied to both vitamin D treated groups combined and compared to those in the placebo group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of CIS patients in each treatment arm free from any evidence of disease activity (No relapses, no new T2 lesions, no gadolinium enhancing lesions).</measure>
    <time_frame>At 24 weeks.</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Serum calcium</measure>
    <time_frame>Every 4 weeks for 24 weeks</time_frame>
    <description>a measure of calcium homeostasis</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability of vitamin D in doses of 5,000IU and 10,000IU daily</measure>
    <time_frame>four weekly assessments over 24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum urea</measure>
    <time_frame>4 weekly over 24 weeks</time_frame>
    <description>a measure of renal function</description>
  </other_outcome>
  <other_outcome>
    <measure>serum creatinine</measure>
    <time_frame>4 weekly over 24 weeks</time_frame>
    <description>a measure of renal function</description>
  </other_outcome>
  <other_outcome>
    <measure>serum 25(OH)D levels</measure>
    <time_frame>4 weekly over 24 weeks</time_frame>
    <description>a measure of response to oral dosing and adherence to therapy.</description>
  </other_outcome>
  <other_outcome>
    <measure>serum parathormone (iPTH)</measure>
    <time_frame>4 weekly over 24 weeks</time_frame>
    <description>a measure of parathyroid function</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Clinically Isolated Syndrome</condition>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Healthy control - 5,000 IU vitamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>13 healthy controls will be administered 5,000 IU vitamin D. Primary outcome and safety outcome measures will be assessed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control - 10,000 IU vitamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>13 healthy controls will be administered 10,000 IU vitamin D. Primary outcome and safety outcome measures will be assessed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CIS - placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>15 patients will be administered placebo and all outcome measures will be assessed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CIS - 5,000 IU vitamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15 patients will be administered 5,000 IU vitamin D and all outcomes will be assessed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CIS - 10,000 IU vitamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15 patients will be administered 10,000 IU of vitamin D and all outcome measures assessed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control - placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>13 control participants who will be administered placebo. These will be assessed for the primary outcome and safety outcomes only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>5000IU vitamin D</intervention_name>
    <description>Vigantol Oil</description>
    <arm_group_label>Healthy control - 5,000 IU vitamin D</arm_group_label>
    <arm_group_label>CIS - 5,000 IU vitamin D</arm_group_label>
    <other_name>Vigantol Oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>10000IU vitamin D</intervention_name>
    <description>Vigantol Oil</description>
    <arm_group_label>Healthy control - 10,000 IU vitamin D</arm_group_label>
    <arm_group_label>CIS - 10,000 IU vitamin D</arm_group_label>
    <other_name>Vigantol Oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Oil</description>
    <arm_group_label>CIS - placebo</arm_group_label>
    <arm_group_label>Healthy control - placebo</arm_group_label>
    <other_name>Placebo Oil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: To be eligible for inclusion, each subject must meet each of the
        following criteria at Screening (Visit 1) and must continue to fulfil these criteria at
        Baseline (Visit 2).

          -  CIS: Patients with a clinically isolated syndrome with onset relapse within the
             previous three months and two or more than two asymptomatic T2 lesions on MRI brain
             scan.

          -  Aged 18-55yrs.

          -  Not receiving any disease modifying therapy.

        Exclusion Criteria:

          -  Patients in whom any disease other than demyelination could explain their signs and
             symptoms.

          -  Participants with known disease of the parathyroids, a history of vitamin D
             intolerance, sarcoidosis, a history of hypercalcaemia of any cause.

          -  Participants with a baseline abnormality in serum urea, creatinine, calcium,
             parathormone.

          -  Participants on thiazide diuretics (hypercalcaemia risk).

          -  Patients with occurrence of a relapse less than six weeks prior to entry to study.

          -  Previous treatment with beta-interferons or glatiramer acetate or steroids in the last
             three months.

          -  Any previous treatment with mitoxantrone or other immunosuppressant.

          -  Participants already taking supplemental vitamin D.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Hutchinson, MB, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Vincent's University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Vincent's University Hospital</name>
      <address>
        <city>Dublin</city>
        <state>Dublin 4</state>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2012</study_first_submitted>
  <study_first_submitted_qc>November 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2012</study_first_posted>
  <last_update_submitted>May 1, 2017</last_update_submitted>
  <last_update_submitted_qc>May 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University College Dublin</investigator_affiliation>
    <investigator_full_name>Professor Michael Hutchinson</investigator_full_name>
    <investigator_title>Consultant Neurologist, Newman Clinical Research Professor</investigator_title>
  </responsible_party>
  <keyword>Clinically isolated syndrome</keyword>
  <keyword>Multiple sclerosis</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Immune response</keyword>
  <keyword>CD4 T cell subsets</keyword>
  <keyword>Cytokine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>all demographic details and outcome measures may be obtained directly from the PI by e-mail</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

